Seeking Alpha

Novo Nordisk Haemophilia A drug does well in Phase III trial

  • Novo Nordisk (NVO) "reports positive results" from the first Phase III trial of its N8-GP treatment for Haemophilia A.
  • The study assessed the safety and efficacy of N8-GP when administered for prophylaxis and when given on-demand in patients who are aged 12 and above.
  • Other than that, Novo provided no other information about the results. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs